261 related articles for article (PubMed ID: 23725151)
1. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
[TBL] [Abstract][Full Text] [Related]
2. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
4. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
5. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Li Y; Yang Y; Shang YM; Zheng H
Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
[TBL] [Abstract][Full Text] [Related]
10. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
[TBL] [Abstract][Full Text] [Related]
12. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
14. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
El-Husseiny K; Motawei H; Ali MS
Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
[TBL] [Abstract][Full Text] [Related]
15. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
[TBL] [Abstract][Full Text] [Related]
18. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
19. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
